drugset / Trial / NCT00370045

Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin

NCT00370045 ↗

Phase 4 Unknown 200 enrolled LifeBridge Health
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare levels of clot formation (platelet aggregation), markers of heart muscle damage, and inflammation in two groups undergoing percutaneous coronary stent implantation. The first group will be on a regimen of high-dose clopidogrel used in combination with bivalirudin plus eptifibatide, and the second group will be on a regimen of high-dose clopidogrel with bivalirudin alone. Clinical outcomes will be determined up to one year after enrollment.

Timeline

Start
2006-03
Primary completion
—
Completion
—

Outcome

Met primary endpoint

paper bivalirudin plus eptifibatide was associated with markedly lower PR at all times PMID 19232896 ↗

paper aggregation; p < 0.001 for all) and reduced mean TIP-FCS (p < 0.05). PMID 19232896 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Bivalirudin Peptide — —
Subject Eptifibatide Other / unclassified — —